EP0629405A1 — Agent for inhibiting a decrease in bone mass in renal osteodystrophy
Assigned to Kureha Corp · Expires 1994-12-21 · 31y expired
What this patent protects
A pharmaceutical composition comprising 24, 25-dihydroxycholecalciferol is useful for the remedy or prophylaxis of disorders associated with renal osteodystrophy. The active compound, 24, 25-(OH)₂-D₃, alone unexpectedly not only improves bone quality but also prohibits bone mass …
USPTO Abstract
A pharmaceutical composition comprising 24, 25-dihydroxycholecalciferol is useful for the remedy or prophylaxis of disorders associated with renal osteodystrophy. The active compound, 24, 25-(OH)₂-D₃, alone unexpectedly not only improves bone quality but also prohibits bone mass decreases in renal osteodystrophy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.